European Union: the approved anti-obesity drug Acomplia
Sanofi Aventis announced that the European Commission has approved the marketing of anti-obesity drug Acomplia (active ingredient: rimonabant). E 'approved, the dose of 20mg. The first launch of the drug is expected in Britain in July. You will then be introduced in Denmark, Ireland, Germany, Finland and Norway, during the second half of 2006. Acomplia is indicated in obese patients (body mass index, BMI, greater than or equal to 30kg/m2) or overweight patients (BMI> 24kg/m2) with associated risk factors (diabetes type 2, dyslipidemia).
0 comments:
Post a Comment